Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib.

Yerlikaya A, Okur E, Ulukaya E.

Tumour Biol. 2012 Oct;33(5):1385-92. doi: 10.1007/s13277-012-0386-3. Epub 2012 Apr 4.

PMID:
22477712
2.

A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line.

Yerlikaya A, Okur E, Baykal AT, Acılan C, Boyacı I, Ulukaya E.

J Proteomics. 2015 Jan 15;113:315-25. doi: 10.1016/j.jprot.2014.09.010. Epub 2014 Oct 8.

PMID:
25305590
3.

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.

Thaler S, Thiede G, Hengstler JG, Schad A, Schmidt M, Sleeman JP.

Int J Cancer. 2015 Aug 1;137(3):686-97. doi: 10.1002/ijc.29404. Epub 2015 Jan 8.

4.
5.

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.

Clin Cancer Res. 2009 Dec 1;15(23):7153-60. doi: 10.1158/1078-0432.CCR-09-1071. Epub 2009 Nov 24.

7.

Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.

Yerlikaya A, Erin N.

Int J Mol Med. 2008 Dec;22(6):817-23.

PMID:
19020781
8.

Synergistic interaction between the novel histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in platinum-sensitive and resistant ovarian carcinoma cells.

Gatti L, Benedetti V, De Cesare M, Corna E, Cincinelli R, Zaffaroni N, Zunino F, Perego P.

J Inorg Biochem. 2012 Aug;113:94-101. doi: 10.1016/j.jinorgbio.2012.04.007. Epub 2012 Apr 27.

PMID:
22717676
9.

Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.

Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R.

Anticancer Res. 2009 Aug;29(8):2961-9.

10.

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.

Cancer Biol Ther. 2010 Jun 1;9(11):936-44. Epub 2010 Jun 27.

PMID:
20418664
11.

Anticancer agent ukrain and bortezomib combination is synergistic in 4T1 breast cancer cells.

Savran B, Yerlikaya A, Erdoğan E, Genç O.

Anticancer Agents Med Chem. 2014 Mar;14(3):466-72.

PMID:
23919744
12.

The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis.

Brooks AD, Ramirez T, Toh U, Onksen J, Elliott PJ, Murphy WJ, Sayers TJ.

Ann N Y Acad Sci. 2005 Nov;1059:160-7.

PMID:
16382051
13.

Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M.

Cancer Res. 2007 Jun 1;67(11):5418-24.

14.

Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.

Bullenkamp J, Raulf N, Ayaz B, Walczak H, Kulms D, Odell E, Thavaraj S, Tavassoli M.

Cell Death Dis. 2014 Oct 23;5:e1489. doi: 10.1038/cddis.2014.455.

15.

Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapeutic agents in gastric cancer cell lines.

Bae SH, Ryoo HM, Kim MK, Lee KH, Sin JI, Hyun MS.

Oncol Rep. 2008 Apr;19(4):1027-32.

PMID:
18357392
16.

Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody.

Shanker A, Brooks AD, Tristan CA, Wine JW, Elliott PJ, Yagita H, Takeda K, Smyth MJ, Murphy WJ, Sayers TJ.

J Natl Cancer Inst. 2008 May 7;100(9):649-62. doi: 10.1093/jnci/djn113. Epub 2008 Apr 29.

17.
18.

Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.

Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.

Leukemia. 2006 Jun;20(6):1017-27.

PMID:
16617327
19.

MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.

Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M.

Cancer Lett. 2010 Dec 28;299(2):161-70. doi: 10.1016/j.canlet.2010.08.015. Epub 2010 Sep 17.

PMID:
20850924
20.

The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.

Hagenbuchner J, Ausserlechner MJ, Porto V, David R, Meister B, Bodner M, Villunger A, Geiger K, Obexer P.

J Biol Chem. 2010 Mar 5;285(10):6904-12. doi: 10.1074/jbc.M109.038331. Epub 2010 Jan 5.

Supplemental Content

Support Center